280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Alumis Inc. Reports Preliminary Cash of $308.6 Million as of December 31, 2025
Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
Other Events
Earnings Release
Investor Presentation
Shareholder votes
Amended material disclosure
Q3
Q2
Q1
Amended Annual Report
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 425
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership